A proof-of-concept study of ARGX-119 in spinal muscular atrophy (SMA)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs ARGX-119 (Primary)
- Indications Spinal muscular atrophy
- Focus Proof of concept; Therapeutic Use
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to an argenx media release, SMA nominated as third indication with proof-of-concept study to start in 2025.